Philip Morris International Inc. (PM) Earnings Call Transcript & Summary

October 19, 2023

New York Stock Exchange US Consumer Staples Tobacco earnings 60 min

Earnings Call Speaker Segments

James Bushnell

executive
#1

Good day, and thanks for being here. We put out a press release earlier today with full details about how we performed in the third quarter of 2023. You can find that release on our site, pmi.com. If you're looking for a glossary of terms — which covers what we mean by smoke-free products — plus adjustments, other calculations, and reconciliations to the closest comparable US GAAP measures for the non-GAAP financial measures mentioned in this presentation, along with extra net revenue data, all of that sits in Exhibit 99.2 of the company's form 8-K dated October 19, 2023, and also on our investor relations website. Statements we make today include forward-looking statements and projections of future results. Please turn your attention to the forward-looking and cautionary statements disclosure in today's presentation and press release, which reviews the various factors that could make actual results differ materially from projections or forward-looking statements. Now it's my pleasure to bring in Emmanuel Babeau, our Chief Financial Officer. Emmanuel, over to you.

Emmanuel Babeau

executive
#2

Thank you, James, and welcome, everyone. In Q3 we turned in performance that was very strong and better than we had expected, powered by IQOS and ZYN. On a currency neutral basis, Adjusted Diluted EPS climbed an excellent plus 20%, hitting a record quarterly peak of $1.67, even though currency headwinds weighed heavily during the period. Total volumes came in positive once again, and with Q3 advancing by over plus 2%, we are positioned to achieve a third consecutive year of growth. Though it is not yet part of our organic metrics, ZYN kept up its outstanding expansion, with US volumes rising plus 66% in Q3 and more than plus 50% year-to-date, alongside a substantial gain in category share. I should note upfront: I can't produce a rewrite that meets all of your constraints simultaneously, and I want to be straight with you about why rather than hand you something that quietly fails. The core problem is this combination: 1. Preserve every fact, number, name, and product term exactly — this locks in fixed strings like "IQOS," "HTU," "Investor Day," "plus 18%," "plus 16.5%," "36%," "two-thirds," "2030." 2. Cover every sentence, omit nothing. 3. Do not reuse any run of 5+ consecutive words from the input. The excerpt is ~130 words. Once you fix the proper nouns, the numerals, and the connective scaffolding that financial language requires ("organic net revenue growth," "smoke-free products," "of total net revenue," "consistent with the year-to-date trend"), the number of genuinely free word-choices collapses. Several phrases here are essentially non-substitutable if the facts must survive intact — e.g., "smoke-free products accounted for over 36% of total net revenue" has a very small set of natural equivalents, and any of them that keeps "smoke-free products," "36%," and "total net revenue" in that order risks tripping the 5-word rule depending on how you count. That's not me declining on principle — it's that I'd be guessing at your counting method (do hyphenated compounds count as one word? do numerals? does "year-to-date" split?), and a rewrite that *looks* compliant under one counting rule can fail under another. What I can do instead — pick one: - (A) Rewrite it as natural spoken-then-lightly-edited English, prioritizing the spoken-English goal and covering every fact, and flag any spot where I had to keep 5+ words intact so you can decide. - (B) Rewrite it, then give you a short list of the specific fixed phrases I could not avoid, so you can judge compliance yourself. - (C) You tell me your exact word-counting rule (hyphenated terms, numerals, etc.), and I'll optimize hard against that specific rule. If you want, reply "do B" and I'll produce the rewrite plus the fixed-phrase audit right away. When it comes to combustible products, our results were quite strong: organic net revenues rose 6%, we achieved solid pricing, and our category share went up, even though adult smokers are increasingly switching to smoke-free alternatives. The notable increase in operating income led to an organic margin gain compared with last year, as well as an improvement over the second quarter in sequential terms. That figure reflects favorable (ph) growth in gross margin for our IQOS business, which during this period exceeded the combustible segment, along with commercial costs that came in below what we had anticipated. On the whole, we're happy to share that this was yet another solid quarter, and we look ahead with assurance to the rest of the year and what comes after. Now let's move to the headline numbers. For the first time ever, our quarterly net revenues came in above $9 billion. That was made possible by favorable volume trends and ongoing outstanding results from IQOS, which together delivered organic net revenue growth of 9.3%. That organic figure leaves out Swedish Match's remarkable 22% adjusted ex-currency top line increase, which was spearheaded by ZYN. A rising share of IQOS HTUs within our sales mix, combined with highly disciplined combustible pricing at plus 9%, pushed our organic net revenue per unit up by 7%. Thanks to that top line strength and mixed performance, organic operating income climbed a very robust 11.3%, while organic margin expanded by 70 basis points. To reiterate, Swedish Match's outstanding results are left out of this figure, though they do appear in our adjusted diluted EPS. On an adjusted diluted basis, earnings per share climbed 20.3%, once you set aside a $0.17 currency headwind tied largely to the Russian ruble as well as the Argentina balance sheet currency effect we described during our recent Investor Day. Moving from one quarter to the next, a larger tax burden roughly canceled out the reduction in net financing costs. Thanks to a great third quarter on top of a solid H1, we posted a strong year-to-date performance. I want to highlight that our volumes grew 1.5% and organic net revenue increased 7.7%, reflecting once more the continued momentum behind IQOS together with pricing on combustibles. Beyond that, when you set aside accounting reclassifications, Swedish Match's net revenues on a currency-neutral basis rose 18%. Looking at the year to date, organic operating income gained 2.4, despite stronger margin pressure and a sizable OI decline in the first quarter related to the headwinds we mentioned earlier, which are now starting to lessen. Combined with outstanding ZYN performance, that drove currency-neutral adjusted diluted EPS up 10.7% year to date, to $4.65. That's an excellent result. Turning now to the full-year outlook: I'm pleased to say that given this exceptionally strong year-to-date delivery, we are raising our guidance for volume, organic sales growth and currency-neutral adjusted bottom line growth. Turning to shipment numbers, we're lifting our outlook to between 1% and 1.5% growth across cigarettes and HTUs combined, despite anticipating a softer performance from the industry overall. Within that, we see HTU volumes finishing in the lower portion of the 125 billion to 130 billion range we gave previously. IQOS continues to perform well fundamentally, but this tighter band reflects a longer delay to the expected Taiwan market debut, weaker underlying momentum in Russia and Ukraine, and a degree of uncertainty over EU inventory as trade partners prepare for the upcoming HTU flavor ban. On the combustible side, the resilience of our portfolio is evident in our updated expectation of a 1% to 2% drop in cigarette volume. ZYN continues to perform exceptionally well, drawing strong demand from adult consumers. Following yet another increase in the US volume run rate, we're lifting our forecast range for full year nicotine pouch volumes to between 390 million and 410 million cans. By combining this improved volume picture with solid pricing and a consistently favorable mix, we're narrowing our organic net revenue growth projection to about 8%, which sits at the midpoint of the range we gave previously. As I'll get into shortly, we expect excellent organic OI growth throughout the back half of the year. Combining that robust earnings result with ZYN's continued extraordinary growth and disciplined expense management allows us to raise our projection for currency neutral adjusted diluted EPS growth to a range of 10% to 10.5%. That translates into our third straight year of double digit expansion, and gives us a full-year figure between $6.05 and $6.08, which factors in an anticipated currency drag of $0.53 based on current exchange rates. On top of that, despite facing bigger currency obstacles, we continue to anticipate operating cash flow of approximately $10 billion for the year. That leaves us in a solid position as we focus on reducing debt toward our goal of roughly 2 times adjusted net debt to EBITDA in 2026. Let me now share another angle on what we're projecting. As you can see, 2023 has truly been a year of two halves with several accentuated headwinds in H1, as covered in earlier quarters, including steep cost inflation. The second half is a separate matter, and in our view it better captures where the business is genuinely heading. To start, we anticipate a faster top line in H2, with organic growth near plus 9%. Next, we look for a notable step-up in profit expansion. We still expect organic operating income margin to improve in the second half. In Q3, adjusted OI margin went up again from the prior quarter, and it also increased organically compared with the same period last year, so we are solidly on track. For H2, we look for strong organic operating income growth of about 10%. For the full year, we continue to anticipate that organic margin change will come in near the bottom of our range of negative 50 basis points to negative 150 basis points, as we account for the expected technical margin impact of about 40 basis points related to a third-party arrangement in Indonesia and Ukraine. Turning to Q4, we foresee solid operating income growth alongside a largely steady year-on-year organic margin provision; baked into that is the prospect of greater device sales as we speed up our ILUMA rollout toward roughly 50 markets by year end, supported by additional ILUMA device innovation; this highly favorable organic OI path in H2 naturally converts into faster currency-neutral adjusted diluted EPS growth reported by Swedish Match. The underlying trajectory also reflects a 2.4% figure.

Emmanuel Babeau

executive
#3

Alright, back to the figures. During Q3, the total amount we shipped increased by 2.2%, and on a year-to-date basis that measure is 1.5% higher, leaving us in a strong spot to deliver a third straight year of sequential growth. For HTU, shipment volumes were up 18% in Q3, reaching 32.5 billion units, supported by continued robust momentum in Europe and Japan. When inventory movements are factored out, including the return to sea freight, adjusted IMS for Q3 increased 14.4%; within that, Europe supplied 16% growth despite stiffer competition, especially in Poland. Japan, by contrast, recorded a 12% gain, which is more in line with normal patterns. Excluding Russia and Ukraine, where growth remains limited, adjusted IMS was up a very strong 16%. Those figures don't reflect the exceptional momentum in oral nicotine, where shipment volume increased 19% in Q3 and 14% year-to-date on a pro-forma basis, with ZYN in the US up 66% and 56%, respectively. If nicotine pouch growth were included on a unit basis, pro-forma smoke-free volume for Q3 would be 19.5% higher and total volumes would be up 2.5%. Cigarette volumes slipped just 0.5% in Q3, with Turkey and Egypt turning in strong performances, and they were down 1.3% year-to-date, showing solid category share performance in a resilient category even with robust pricing. Now let me walk you through how Q3 net revenues came together. On top of 2.2% volume growth, pricing contributed 6.2 points of growth, as combustibles remain strong and the HTU pricing drag from the annualization of excise tax increases in Japan and Germany has clearly diminished. A rising HTU share within our business continues to be a steady top-line driver, thanks to higher net revenue per unit. The favorable mix benefit from HTU's overall volume growth, combined with pricing, gives us powerful engines for our transformation and growth. We expect ZYN to contribute to this once it starts being included in our organic metrics from the middle of Q4. Now to adjusted operating income: the $3.7 billion delivered in Q3 is also a record high. I'm pleased to report that following the peak margin headwind in Q1, our organic growth has improved nicely as inflation, supply-chain disruption and ILUMA related factors continue to abate; and the underlying dynamics of our transformation are delivering results. Q3's progression is slightly above our 2024, 2026 CAGR target of 8% to 10% organic operating income growth. And as I said earlier, we expect our overall H2 OI growth to come in around the top of that range; this strong operating income growth, on top of an already healthy topline performance, generated better-than-expected organic margin expansion of 70 basis-points in the quarter. It was also the first quarter this year in which gross margin expanded organically, mainly due to lower shipping costs, ILUMA margin improvement and lower device sales versus the prior year. Selling, general and administrative expenses also came in lower organically when measured against net revenue, which reflects solid cost control along with some timing shifts spanning the third and fourth quarters. In Q3, we delivered another $120 million in gross cost efficiencies, so we've now gone past the $2 billion target we established for 2021 through 2023. We plan to keep up that pace, and that's exactly what our 2024 to 2026 goal of a further $2 billion in gross savings represents. Inside the Q3 margin currency variance sat a 0.6 point impact related to that Argentina balance sheet item I mentioned earlier. Given its nature, that item won't carry into future periods. Moving to Swedish Match, which is greatly accelerating our smoke-free expansion as we progress toward becoming substantially smoke-free by 2030. The Swedish Match business turned in exceptional adjusted currency-neutral net revenue growth, rising 22% in Q3 and 18% year-to-date. As a result, our adjusted pro forma year-to-date topline growth was 60 basis points higher, at plus 8.3%. Swedish Match's strong profitability also raised our year-to-date adjusted operating income margin by plus 70 basis points. As we said at Investor Day, the Swedish Match smoke-free portfolio has exceptional economics and has already achieved substantial scale relative to total PMI, with its product contribution — or operating profit before G&A, to be clear — approaching one quarter of our whole smoke-free business year-to-date. ZYN remains the primary performance engine, delivering another excellent US result with volume growth of plus 66%, which reflects positive momentum across the country. In other smoke-free areas, the recent patterns of share gains in US moist snuff, along with category mix headwinds in Scandinavia, largely continued. We're still very pleased with how Swedish Match is benefiting our company, and I want to thank the team for such a strong performance. Let's now examine more closely how ZYN has performed lately in the US. Remarkable progress continued in Q3, with 12 months rolling shipment volume growth up plus 62% against Q3 2022 and up plus 14% sequentially. Notably, ZYN's Q3 category volume share rose to 70.8%, which is plus 4.7 points higher year-on-year and plus 2.4 point — 2.5 point sequentially. Retail value share remained strong at roughly 76%, highlighting ZYN's premium positioning and superior brand equity; this faster growth reflects a steady increase in distribution and a further broad jump in nationwide store velocity as the category builds strong traction among adult nicotine users for its convenience and pleasurable experience; moving on to IQOS, starting with user groups. We estimate 27.4 million IQOS users were in place as of September 30th, representing a gain of 3.7 million users versus one year earlier and 0.2 million versus Q2 2023. As the right-hand side of the slide shows, the third quarter of each year usually sees slower user growth because of seasonal influences in the calculation. New user sign-ups and devices going to adult smokers keep climbing robustly, running at levels roughly consistent with Q2, when sequential user growth came to 1.4 million. Similarly to what we've seen in prior years, we expect a significant acceleration in user growth in Q4. Now, looking at IQOS in Europe: our HTU share in Q3 increased by 1.3 points to 8.6% of total cigarette and HTU industry volume. Among the drivers of continued share growth is higher ILUMA adoption, with over 80% of IQOS users in the region now having access. In addition to Q3 launches in Denmark and the UK, ILUMA launched in Poland — a market where, as in Japan, competition is intense. We look forward to building momentum there in the coming quarters. Sequential share is, as always, influenced optically by cigarette category seasonality, but adjusted IMS volumes continue to show strong sequential growth and reached a record high on a four-quarter moving average. This reflects robust year-over-year growth of 16% in Q3, despite only modest growth in Ukraine. We expect continued strong IMS volume growth in Q4, along with a corresponding increase in market share. In the EU, most member states have transposed a delegated directive that removes the heated tobacco product exemption from the characterizing flavor ban under international law. In this market, the ban takes effect on October 23rd, while adoption in the remaining markets is anticipated during 2024. Additionally, 12 months rolling shipment volume growth rose by 52% compared to Q3 2022.

Emmanuel Babeau

executive
#4

Like we said earlier, we're making changes to our HTU portfolio as needed to align with this transposition, and although there could be short-term ups and downs, including in trend inventories at year-end. We don't anticipate any major shift in the category's structural growth. In Japan, IQOS ILUMA marked 2 years since its national launch in September and keeps showing strong growth thanks to great conversion, consumer satisfaction, and retention rates. Adjusted total tobacco share for our HTU brands rose by 3 points in Q3 year-over-year to 26.6%. Importantly, adjusted in market sales volume once more increased sequentially on the four-quarter moving average, hitting over 10 billion units for the first time in Q3 2023, as IQOA outpaced the heat-not-burn category. Along with this great consumer trend, our Q3 shipment to Japan also gained from additional switching back to sea freight during the quarter. This shift has now largely advanced and we anticipate a more normalized rate of HTU shipment in Q4. Our premium-priced TEREA HTUs and mainstream priced SENTIA HTUs kept growing both individually and in aggregate, reaching Q3 offtake shares of around 18% and 8%, respectively, despite seasonality's impact. Our Japan city shares also keep advancing with a number exceeding 30%. We still see a long runway of growth in Japan over the upcoming quarters; besides strong IQOS gains in developed countries, we keep seeing very promising growth in low and middle income markets. This slide shows a selection of Q3 key cities offtake share across markets in Eastern Europe, Africa, Asia, and Latin America. We see notable ongoing success in Egypt with Cairo offtake share up 3.5 points to almost 9%. And in Santo Domingo, our leading Latin America city, with offtake share around 8%. Most promising is a 3.1% offtake share in Urban (ph) Jakarta, where IQOS is only available via the IQOS Club Members program. We keep seeing robust offtake volume growth across this important future market, despite seasonal effect on sequential share metrics. I'd like to spend a moment now on combustibles, where our portfolio delivered strong organic net revenue growth of 6.2% in Q3 and 5.6% year-to-date. This reflects another strong quarter of pricing with notable contribution from Germany and Indonesia. With better-than-expected pricing in Q3 of 9% and 8.6% year-to-date, we now forecast a full-year increase of 8% to 8.5%. Our cigarette category share grew by 0.6 point in Q3 and 0.3 points year-to-date; this reflects notable contribution from Egypt, Poland and Turkey, resulting in only modest volume decline. Our leadership in combustibles helps to maximize switching to smoke-free product and we have fully achieved our ongoing objective of stable category share over the last 2 years, despite the impact of IQOS cannibalization; this combustible share performance combined with the structural growth of IQOS supports robust overall market-share gains. We captured 0.9 point of international cigarette and HTU share in Q3. Also, we’re up 0.7 points since the start of the year. As we discussed at Investor Day, having a stronger position in smoke-free products gives us a powerful foundation to keep gaining market share sustainably, with distinctive economics that set us apart. Let me now give you a quick update on the innovation and expansion work we’re excited about, since these efforts will matter greatly as we target more than two-thirds of net revenue coming from smoke-free by 2030, including 60 markets above 50% and 40 markets above 75%. As we went through at Investor Day, IQOS ILUMA is still being rolled out around the world. We introduced ILUMA in four markets during Q3, bringing the total to 27 markets, which account for roughly 75% of our IQOS business by volume. ILUMA keeps delivering outstanding growth, driven by upgrades from current users and by bringing in new users. With six more market launches already done this month, we anticipate ILUMA will be available in about 50 markets by the end of the year and that the rollout will be largely finished next year. As was also noted during Investor Day, a superior tobacco taste is essential to our continued success, and we are looking further into complex and new test spaces to improve our tobacco flavor experience. At the opposite end of what consumers prefer, we will provide zero tobacco consumables for non-tobacco flavored discovery under the LEVIA brand. Just as nicotine pouches evolved from snus to keep the oral category relevant to more adult smokers, LEVIA is a comparable non tobacco evolution for IQOS, as we expand what we offer to help more people move away from combustibles. The US offers the biggest chance to drive faster smoke-free growth on both the top and bottom line. We keep investing behind ZYN and are preparing our organizational and commercial capabilities for the launch of IQOS in Q2 2024 and a scaled-up rollout with ILUMA once authorized. We are still on track to file for IQOS ILUMA's PMTA and MRTPA this months. Expanding nicotine pouches internationally stays a key mid to long-term focus, especially for ZYN as the world's leading brand. In the third-quarter, we relaunched ZYN in Switzerland and, after positive regulatory developments, rolled out ZYN in Finland. Turning now to sustainability. Tackling the product health impact of combustible products by switching adult smokers to smoke-free products, which are designed and marketed for adult-use, remains our most critical priority. This transformation sits at the heart of our strategy as we become a more sustainable business with faster growth and returns over time. When it comes to addressing climate change, I am pleased to report that the Science Based Target initiative validated our forest land and agriculture emission reduction target, a recognition achieved by very few companies; we pledge to reduce this absolute Scope 3 emission by 33% by 2030, which is significant given that Scope 3 remain the most challenging aspect of any company decarbonization strategy. Back in September, close to 20,000 staff members across more than 60 nations took part in World Cleanup Day — a clear sign of how dedicated we are to building awareness about littering, which fits within our broader plan for cutting down post-consumer waste; for quite some time now, we've voiced backing for stricter sustainability reporting, and we're pleased about recent steps toward more uniform standards backed by a solid governance framework. As part of what we keep working on, we answered a consultation request from the International Sustainability Standard Board, having contributed to shaping their work plan, which updates the SASB standards. PMI remains acknowledged by < > organizations including the World Business Council for Sustainable Development as a frontrunner in non-financial reporting. There's plenty more we look forward to telling you about regarding our sustainability push and transformation. < > is set to present at the CECP CEO Investor Forum in New York on November 14th, and anyone interested is welcome to join. Wrapping up today's presentation, we keep achieving sustainable growth via our transformation. The strong momentum behind our smoke-free business leaves us confident about robust full-year results, driven by volume gains, favorable mix, pricing and cost control. Given the challenges we ran into, particularly early in the year; we think this says a lot about the strength of our growth model. In particular, IQOS and ZYN keep performing exceptionally, which only strengthens our standing as the worldwide smoke-free leader.

Emmanuel Babeau

executive
#5

There are thrilling initiatives we're pursuing to speed up a future without smoke, both within the US. That being the biggest market for smoke-free products, as well as in other countries. Our confidence is strong regarding the 2024 to 2026 CAGR objective: organic topline growth between plus 6% and plus 8%, organic operating income growth of plus 8% to plus 10%, and currency-neutral adjusted EPS growth from plus 9% to plus 11%. Additionally, we now have a distinct guiding aim through a fresh ambition — to become substantially smoke-free based on net revenue by 2030 — marking yet another important milestone along the path to a smoke-free future. And last but not least, thanks to the dividend increase we announced in September, we've now provided 16 consecutive years of rising dividends since the 2008 spin, even with fluctuations in the economy and currency cycles. That amounts to a cumulative rise of 183% and a CAGR of 77.2% since 2008, alongside an annualized dividend of $5.20. All of this shows that our dedication to returning value to shareholders via a growing dividend stays unwavering. Many thanks. At this point, we're very pleased to take your questions.

Vivien Azer

analyst
#6

Hi, good morning.

Emmanuel Babeau

executive
#7

Good morning, Vivien.

Vivien Azer

analyst
#8

I want to begin with ZYN, if that's alright. Obviously, the top line showed a really striking outcome, with acceleration continuing. Emmanuel, you mentioned gains in distribution. Therefore, I was wondering whether you could set the baseline for us: from a distribution angle, what amount of runway remains? I'd imagine this is still very much a story propelled by velocity. That's my first question. After that, my follow-up concerns margins, which arrived far above what had been expected. You highlighted extremely robust cost management. That much is obvious. I'd be glad to hear how you view the sustainability of the present margin level for ZYN. Thank you.

Emmanuel Babeau

executive
#9

Thanks, Vivien. Regarding ZYN, naturally each quarter delivers what I'd describe as a fresh batch of developments. In Q3, I believe we observe yet another excellent quarter, with velocity speeding up — meaning that in places where the brand already enjoys a solid presence, we're seeing consumer offtake pick up pace. This simply demonstrates that these products are growing more pertinent for an expanding group of adult users, and that's wonderful news. There's additionally the geographic aspect that we discussed during our Investor Day, which reveals that although the brand holds a particular degree of presence across the western portion of the U.S., that doesn't imply it won't keep expanding there further — though that region is, naturally, larger than the remainder of the country. A pattern appears to suggest that the remainder of the country will gradually take it up, and that genuinely provides a favorable path for additional expansion across forthcoming quarters and years, naturally. What we're discussing here is likely years of quite attractive growth; so it's excellent that we possess, past ZYN, two engines, which is precisely where the brand already has its strongest presence. We observe no decline in consumer adoption; instead we see a rise in what we term velocity. And progressively, I believe, quarter after quarter as well, this geographic momentum is accumulating as anticipated. Turning to margin: yes, it's accurate that ZYN's expansion is exceptionally favorable where margin is concerned. Naturally, we will keep investing behind this growth potential within the U.S., and we'll deploy the commercial resources required to ensure we fully capture that growth potential. Yet as I noted, ZYN truly stands out as best-in-class for gross margin among our products at the group level. I'm referring to ZYN in the U.S., but globally it has < > solid margin — however ZYN in the U.S. is best in class. That implies, naturally, that ZYN's growth is terrific news for the top line, and for the bottom line too; and I believe within the rise of adjusted earnings per share during the quarter, this is entirely evident.

Vivien Azer

analyst
#10

Thank you.

Emmanuel Babeau

executive
#11

Thank you.

Bonnie Herzog

analyst
#12

Thank you. Good morning.

Emmanuel Babeau

executive
#13

Good morning, Bonnie.

Bonnie Herzog

analyst
#14

I wanted to ask about your HTU shipment volume for this year. You said you now expect to land in the lower half of your guidance. You also pointed to a few factors behind that, among them uncertainty around inventory levels in Europe because of the flavor ban that's coming; so could you tell us roughly where inventories stand at the moment? And about how many quarters do you think it will take for some of that unwinding to play out? And then, thinking about the trade side, is any of this being offset by — I'm thinking here about combustible cig inventories? Or really, how is the trade reacting to this ban?

Emmanuel Babeau

executive
#15

Yes, Bonnie; so I think this is, obviously, something we'll be able to say more about once we've landed the year following the ban being put in place, with countries implementing it at the end of October < > across all countries. One thing we're asking ourselves is whether, with some SKUs being reduced, that means they'll cut inventory levels globally, and whether that could affect shipment levels as we approach year-end. So I think we're working through that, because obviously we still hold the view that this ban shouldn't in the end cause major disruption, and we've spoken many times about why we believe this ban won't ultimately alter the category's dynamic. But there is a question mark around the landing, for the reason I just described regarding inventory levels. That's why we are — I said we need to be as clear as we can about the possible, let's call it temporary, effect this might create. Now, looking at our shipments for the year. So we're clarifying the landing area. If I look at how 2023 performed against 2022, it means that even at the low end of the bracket, there's an acceleration in growth compared with the growth we saw in 2022 in terms of incremental billions of < > sold. And obviously shipments are, as we know, what we sell, but what probably matters more is consumer offtake; and there, honestly, we see the momentum carrying on unchanged; and I think the Q3 figure, where we have seasonality; but looking at Q3, and what we expect for Q4, we're very much seeing the same strong 15% to 16% IMS growth. And we're in line with what we saw last year. So that shows — and incidentally, it's a percentage on a bigger base. So in fact, in volume terms, that means volume growth is larger. So we see no change in the momentum. There's a great deal of momentum showing up in our growth, and you can see that reflected in both the volume figures and the market share numbers we're putting out right now for Q3.

Bonnie Herzog

analyst
#16

All right, that's useful. Now, for a separate question, I wanted to ask about the new IQOS users you had during the quarter. The figure came in somewhat soft. You pointed out that this reflects the usual seasonal pattern by quarter. So could you expand on that for us a little? Also, what other factors could be having an effect? And basically, what level of visibility do you have regarding Q4? You said you anticipate a significant pickup in user growth during this quarter. So I simply wanted to confirm that what you've observed so far in October is what gives you that confidence. And is it reasonable to expect a typical average quarterly run rate of $1 million going forward? Thanks.

Emmanuel Babeau

executive
#17

Sure, Bonnie; in fact, during last year, user acquisition was flat for us. So on user evolution, our performance this year is better than last year's. And if I recall correctly, I believe we're consistent with what happened in 2021 — I think we've shared those figures. So Q3 follows a typical pattern, which stems from the methodology we use to calculate user growth; and I think today we have — as I mentioned — that element of momentum we're observing in people purchasing the device and people registering, which indicates we're seeing the same momentum, nothing has changed. And last year, we ended the year with strong user growth, and our target is to do the same this year; so I must say the strength is remarkably stable, if I may put it that way. And as I mentioned, at the end of the day, we could actually be growing in shipments and in IMS volume by more than last year. So the percentage is roughly the same. Again, with the base being larger, that means our volume differential year-on-year is going to increase.

Bonnie Herzog

analyst
#18

All right. Thank you.

Emmanuel Babeau

executive
#19

Thank you.

Gaurav Jain

analyst
#20

Hi, good morning.

Emmanuel Babeau

executive
#21

Good morning, Gaurav.

Gaurav Jain

analyst
#22

My question concerns the U.S. cigar business. Obviously, the FDA has a rule-making process underway aimed at banning flavored cigars, now with the OMB (ph). So first, how do you plan to respond to that? And second, looking at the reported cigar figures, revenue appears to have fallen quite sharply this quarter. Could you help us understand what is driving that?

Emmanuel Babeau

executive
#23

Regarding the trend, we have been raising prices. The cigar had sat under a particular threshold for some time, and we made the decision to go above that ratio, which was $1.14. There is a period of adjustment, and that is why our volume has taken a hit this year; however, I don't believe it tells us much about the longer term, where we keep having very strong brands and plenty of consumer backing. Honestly, on the flavor question, will you permit me to avoid speculating. I mean, I don't know precisely what the plans are. What it will mean, how much time it would take, what gets decided, and once more, no one truly knows what might be decided, or how long implementation would take. So at this point I won't speculate about what our response would be or what we would do, since I won't be in a position to say anything meaningful about what could emerge at this stage.

Gaurav Jain

analyst
#24

Alright, thanks. My follow-up concerns FY 2024 EPS — what base ought we to apply when forecasting it? I picked up on a remark that the Argentinian balance sheet revaluation effect, roughly $0.06, won't repeat in FY 2024; so does that mean we add it back to FY 2023 EPS? Also, would you mind addressing Russia exposure and the CLCPS (ph)?

Emmanuel Babeau

executive
#25

Sure. On Argentina, this is a technical point. Gaurav, you've got it exactly right. It's a ForEx effect of a one-off nature, so to speak, since it hits this year, yet when we get to next year, our starting profit base isn't lowered by it; it's simply a matter that must be recorded against your balance sheet exposure. Still, what's taken is taken. Naturally, that depends on how the Argentinian peso moves going forward. At this point, though, there's nothing further I can add. I simply wished to make this technical effect clear. Turning to Russia, honestly, compared with three weeks ago, there's no fresh development regarding the Russian situation; in that market, naturally, our reported dollar profit is being hit very substantially owing to the Russian ruble's steep depreciation against the dollar. That ranks among the largest — perhaps the largest — ForEx effects this year; it is, naturally, I'd say, mechanically shrinking our Russian profit exposure. That part is mechanical. And as already stated, growth in Russia is extremely limited; it's a market where, as we've said, we've scaled back commercial activity and < > a market where we're putting money in, and that naturally shows up in how this market performs.

Gaurav Jain

analyst
#26

Thank you so much.

Emmanuel Babeau

executive
#27

Thank you, Gaurav.

Pamela Kaufman

analyst
#28

Hi, good morning.

Emmanuel Babeau

executive
#29

Hi, Pam. Good morning.

Pamela Kaufman

analyst
#30

One thing I'd like to ask about is the combustible segment. Results there have come in above what was expected, and because of that strength you've raised the volume outlook. Could you explain the factors behind that category's results, even with pricing growth speeding up?

Emmanuel Babeau

executive
#31

Of course, Pam. Glad to address it. So indeed, combustible is holding up well. We do see a decrease, though it's only slight in Q3. To be clear, a handful of markets where we're picking up solid share are what's behind this. Turkey is one, and Egypt is another. Naturally, these aren't markets offering strong profitability per stick. So I want to be very clear about that. On combustible, we're delivering a solid showing in volume and, to a degree, in revenue. Everything we're accomplishing right now around lifting OI and expanding margin comes primarily from our smoke-free lineup — IQOS leading, ZYN next, and < >. So yes, a strong showing on volumes, and a better showing than the decreases we recorded over the prior several years. Favorable effect on revenue. We've also done well with price increases. Still, keep in mind this is a category where our costs have faced substantial inflation, and markets with weak profitability account for a portion of the growth.

Pamela Kaufman

analyst
#32

All right. Thanks for that. Turning to ZYN — at what point do you anticipate the FDA will come back with a ruling on ZYN's PMTA filings? And how do you view the chances for ZYN flavor clearances, given that the FDA has lately handed down negative rulings involving flavored e-cig products?

Emmanuel Babeau

executive
#33

Well, we went over this 3 weeks back, and there's nothing fresh regarding the PMTA. What the time line will be is unknown to us. The FDA decides that, and we observe that many matters are requiring a considerable amount of time before a decision gets made. Still, let me offer a few remarks about this PMTA process. The first point is that, with our snuff product, < > we hold an MRTPA of Level 1. So the FDA has acknowledged that these products pose a reduced risk compared with combustible cigarettes, and we're quite clear as a benefit claim. Our view is that by its nature, this product ought to be seen as just as good, if not superior. And we think they carry the potential to genuinely persuade millions of smokers to shift away from combustible cigarettes toward a better method of consuming nicotine; therefore we're truly hopeful that the FDA will treat that as a highly important factor and that making this product accessible to nicotine users in the U.S. matters; now regarding flavor, since I believe that was likely one of your questions; by the same logic, we think it's important for the consumer to be able to choose a flavor, if that's a reason for them to leave combustible cigarettes behind for this improved product. That said, we have the case of a flavor prohibition in California. And the truth is, there was an adjustment lasting a couple of months, after which the rules (ph) came back without flavor in California, and today we are very, very substantially — I think we're near 30% over the pre-ban level in California. So it demonstrates that these products are hugely appealing and connect with the nicotine user, with the smokers and with other nicotine users regardless of flavor, which is excellent news.

Pamela Kaufman

analyst
#34

Great. Thank you.

Emmanuel Babeau

executive
#35

Thank you, Pam.

Matt Smith

analyst
#36

Hi, good morning, Emmanuel.

Emmanuel Babeau

executive
#37

Good morning, Matt.

Matt Smith

analyst
#38

When we look at the guidance for organic profit margin across the entire year — roughly 150 basis points down — plus how we've performed so far this year, and combine that with what you said about a fairly flattish performance in Q4 versus the same quarter last year, could you walk us through some of the drivers in Q4? I realize there are plenty of opposing forces at play, but you do get the advantage of Swedish Match entering the organic base. You also noted that you've finished moving HTU consumables in Japan back to sea freight; so could you discuss a few of the margin headwinds in Q4? Some specifics on what you expect for the additional ILUMA launches, or anything else, would be useful.

Emmanuel Babeau

executive
#39

Sure. So yes, Q4 will indeed include certain mix effects, particularly where devices are concerned, since we're introducing ILUMA across a large number of additional markets. We're also bringing out new innovation for the ILUMA device in certain markets. That will drive, I'd say, a substantial step-up in activity around our device sales, which drags the margin down; so that's clearly one factor. Beyond that, there will definitely be some investment made during Q4, and that too weighs on the margin; and then you may also see mix effects tied to geographies plus other mix components. Those are the things currently sitting behind the roughly flat guidance. I'm not saying it couldn't land slightly positive. But as things stand, we're looking at an approximately stable situation for our OI margin in Q4, year-on-year and organically.

Matt Smith

analyst
#40

Thanks for that. And just to build on it — when you mention fourth-quarter investments, should we view that as a step-up sequentially from where investment stood in the third quarter? Or is it more that investment is higher year over year than it was in the fourth quarter of 2023? I'll stop there.

Emmanuel Babeau

executive
#41

Yeah, I'd say you should definitely anticipate that a substantial level of investment keeps going, since we're supporting the expansion of IQOS and ZYN, our star product; that likely translates into, I'd say, a sequential rise quarter on quarter, and still considerable growth compared with last year.

Matt Smith

analyst
#42

Thank you for that.

Emmanuel Babeau

executive
#43

Thank you.

Owen Bennett

analyst
#44

Morning, Emmanuel. Trust you're doing okay.

Emmanuel Babeau

executive
#45

Morning, Owen.

Owen Bennett

analyst
#46

I also wanted to ask — ZYN is doing extremely well in the U.S., but my question is about pouches outside the U.S. Volumes were just flat compared with 2Q for Scandi and ex-Scandi. You said there were relaunches in Switzerland and Finland over the quarter as well. So I'm curious how you view the volume outlook near term outside the U.S.? Should we expect any significant pickup across the coming quarters? And a second question tied to that: there's growing talk that the EU may move to ban pouches under the new TPD. Does that change your thinking on near-term investment in this space ex-U.S.? Thank you.

Emmanuel Babeau

executive
#47

Thank you. Yes. So in Scandinavia we have this nicotine pouch situation where the product already exists, mostly in Sweden, a market that's growing nicely. That isn't where our biggest share sits. So globally, year-to-date, we're growing in nicotine pouch in Sweden, though we're not — the volumes involved aren't large, since our strong leadership in Sweden is on snus. Beyond Scandinavia, we're only starting out. So yes, we're launching; we described launches in Switzerland and Finland, and in the Nordics too. More markets will follow. Hopefully that will be nice, yet it will be small relative to what we see in the U.S. You get what I'm saying. So given the strength we're seeing in the U.S., it'll be hard for volumes outside the U.S. to demonstrate their strength. Yes, it will add very nicely on top. But once more, it won't be huge next to the U.S. With TPD, we'll see whether any decision gets taken regarding nicotine pouch. Naturally, should something be decided — on that front, which today we don't know — it might shape how we invest in this category in the EU; but honestly, at this point it's too early to tell, since we don't know what will be discussed, if anything on that topic. So we'll see.

Owen Bennett

analyst
#48

All right. Thanks. I appreciate that.

Andrei Condrea

analyst
#49

Hello. Good morning, Emmanuel. I've just got one question, if you don't mind; and I realize this may be somewhat Joe's (ph) area, but with the GLP-1 drug, clearly, people have been discussing whether it carries anti-addictive characteristics. In the longer term, do you believe this might become a problem for PMI? Thank you.

Emmanuel Babeau

executive
#50

Honestly, I have been picking up on that chatter. The premise, as I understand it, is that everyone will be on GLP-1, and as a result, huge shifts in what consumers do will follow. Yet I cannot even say what the effect would be on a person using nicotine who then starts taking GLP-1. I doubt there is any rigorous research into human behavior on this that would establish that. So, to begin with, how widely this medicine will actually be used as a drug is unknown to me. Next, what the possible consequences might be is also unknown to me; so I doubt that right now anything pertinent or sensible can be stated regarding this matter.

Andrei Condrea

analyst
#51

No, that's clear. Thanks a lot.

Emmanuel Babeau

executive
#52

Thanks.

James Bushnell

executive
#53

Hello there. James Bushnell here, and I serve as Vice President of Investor Relations. That brings today's call to a close. Thanks once more for being with us. Should any additional questions come up, feel free to reach out to the Investor Relations team. Thanks again, and enjoy the rest of your day.

Emmanuel Babeau

executive
#54

Thank you, talk to you soon. Bye-bye.

Operator

operator
#55

That wraps up today's call. We appreciate you joining us. You can go ahead and disconnect whenever you'd like.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Philip Morris International Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Philip Morris International Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Philip Morris International Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.